Your browser is no longer supported. Please, upgrade your browser.
APVO Aptevo Therapeutics Inc. daily Stock Chart
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-11.15 Insider Own8.08% Shs Outstand3.23M Perf Week-3.94%
Market Cap22.33M Forward P/E- EPS next Y-7.61 Insider Trans0.00% Shs Float2.98M Perf Month-12.44%
Income-36.20M PEG- EPS next Q-2.05 Inst Own35.00% Short Float3.36% Perf Quarter-16.40%
Sales18.50M P/S1.21 EPS this Y54.10% Inst Trans- Short Ratio1.40 Perf Half Y75.58%
Book/sh2.68 P/B2.55 EPS next Y-3.40% ROA-48.20% Target Price- Perf Year-23.69%
Cash/sh- P/C- EPS next 5Y- ROE-137.20% 52W Range2.94 - 11.73 Perf YTD-25.46%
Dividend- P/FCF- EPS past 5Y15.40% ROI- 52W High-41.77% Beta2.50
Dividend %- Quick Ratio- Sales past 5Y-6.60% Gross Margin45.50% 52W Low131.98% ATR0.32
Employees80 Current Ratio1.50 Sales Q/Q-96.50% Oper. Margin- RSI (14)31.18 Volatility2.20% 4.75%
OptionableNo Debt/Eq0.00 EPS Q/Q37.50% Profit Margin- Rel Volume0.17 Prev Close6.98
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume71.40K Price6.83
Recom1.70 SMA20-7.30% SMA50-12.46% SMA2000.84% Volume12,460 Change-2.15%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Sep-01-20 09:00AM  
Aug-14-20 09:00AM  
Aug-06-20 09:00AM  
Jul-21-20 09:00AM  
Jun-30-20 12:00PM  
Jun-29-20 09:00AM  
Jun-25-20 09:00AM  
Jun-10-20 09:00AM  
May-13-20 09:00AM  
Apr-14-20 09:00AM  
Mar-25-20 09:00AM  
Mar-16-20 09:00AM  
Feb-28-20 09:05AM  
Jan-30-20 09:00AM  
Jan-13-20 08:00AM  
Dec-19-19 03:50PM  
Dec-06-19 09:00AM  
Nov-12-19 09:00AM  
Nov-08-19 09:00AM  
Nov-07-19 09:00AM  
Oct-04-19 07:32AM  
Oct-03-19 04:02PM  
Sep-19-19 09:00AM  
Aug-09-19 09:00AM  
Aug-07-19 09:02AM  
Jul-25-19 04:32PM  
Jun-25-19 09:00AM  
May-09-19 09:00AM  
Apr-29-19 10:21AM  
Apr-26-19 08:31AM  
Apr-15-19 09:00AM  
Apr-11-19 12:26PM  
Apr-02-19 09:02AM  
Mar-25-19 09:02AM  
Mar-20-19 09:02AM  
Mar-18-19 09:00AM  
Mar-14-19 10:28AM  
Mar-07-19 09:13AM  
Mar-06-19 04:37PM  
Jan-07-19 08:30AM  
Jan-03-19 09:02AM  
Dec-21-18 09:00AM  
Dec-20-18 12:57PM  
Dec-13-18 09:02AM  
Dec-11-18 07:20AM  
Nov-20-18 09:00AM  
Nov-14-18 04:02PM  
Nov-09-18 12:00AM  
Oct-24-18 09:00AM  
Oct-10-18 08:40AM  
Sep-25-18 11:29AM  
Sep-05-18 11:36AM  
Aug-31-18 02:46PM  
Aug-09-18 09:00AM  
Aug-07-18 09:00AM  
Aug-06-18 08:10AM  
May-29-18 09:00AM  
May-15-18 07:40AM  
May-10-18 09:00AM  
May-08-18 09:02AM  
May-01-18 09:00AM  
Apr-30-18 07:50AM  
Apr-20-18 08:35PM  
Apr-16-18 09:02AM  
Mar-19-18 08:20AM  
Mar-13-18 09:02AM  
Mar-12-18 09:02AM  
Feb-27-18 09:02AM  
Jan-17-18 08:10AM  
Jan-11-18 09:04AM  
Jan-08-18 09:00AM  
Jan-03-18 08:17AM  
Dec-27-17 10:58AM  
Dec-19-17 09:05AM  
Dec-11-17 01:28PM  
Nov-29-17 10:58AM  
Nov-28-17 07:02AM  
Nov-21-17 06:39PM  
Nov-14-17 04:02PM  
Nov-09-17 04:30PM  
Nov-01-17 11:50AM  
Oct-30-17 09:02AM  
Oct-24-17 09:00AM  
Oct-16-17 09:02AM  
Oct-10-17 08:31AM  
Oct-06-17 10:37AM  
Oct-02-17 09:00AM  
Sep-28-17 04:45PM  
Aug-31-17 05:17PM  
Aug-25-17 11:29AM  
Aug-17-17 07:00AM  
Aug-10-17 09:02AM  
Aug-01-17 04:12PM  
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.